Potency assays for therapeutic live whole cell cancer vaccines

Biologicals

Volumn 35, Issue 2, 2007, Pages 107-113

  Petricciani, John ^a,b   Egan, William ^a,c   Vicari, Giuseppe ^d   Furesz, John ^e   Schild, Geoffrey ^f  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CancerVax Corporation   (United States)

^c Ophthalmology Division   (Turkey)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e Bureau of Biologics   (Canada)

^f NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Cancer; Cells; Potency; Vaccine

Indexed keywords

ALPHA INTERFERON; BACTERIAL VACCINE; BETA INTERFERON; BIOLOGICAL MARKER; CANCER VACCINE; CELL ANTIGEN; GAMMA INTERFERON; INACTIVATED VIRUS VACCINE; LIVE VACCINE;

ALBERS SCHOENBERG DISEASE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; BIOLOGICAL MODEL; CANCER IMMUNOLOGY; CANCER INHIBITION; CELL DIVISION; CELL LINE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL STUDY; CONCEPTUAL FRAMEWORK; CONDYLOMA ACUMINATUM; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG POTENCY; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; KAPOSI SARCOMA; MELANOMA; MIXED LYMPHOCYTE CULTURE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; SEROLOGY; WHOLE CELL;

ANIMALS; ANTIGENS, NEOPLASM; BACTERIAL VACCINES; BIOLOGICAL ASSAY; CANCER VACCINES; CELL DIVISION; CELL SURVIVAL; COMMUNICABLE DISEASES; HUMANS; NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VACCINES, ATTENUATED;

ANIMALIA;

EID: 33947247556     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2006.05.001     Document Type: Article

References (23)

1. Scott A.M., and Cebon J. Clinical promise of tumour immunology. Lancet 349 suppl II (1997) 19-22
2. Development of therapeutic cancer vaccines. In: Brown F., and Petricciani J. (Eds). Developmental Biology vol. 116 (2004), Karger, Basel
3. International Conference on Harmonization Guideline Q6B, Specifications: test procedures and acceptance criteria for biotechnological/biological products, 10 March 1999.
4. WHO Guidelines on nonclinical evaluation of vaccines, adopted by the ECBS, 17-21 November 2003, Annex 1. www.who.int/biologicals/publications/trs/areas/vaccines/nonclinical_evaluation.
5. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Guidelines for the production and quality control of synthetic peptide vaccines. Annex 1. Technical Report Series (TRS) 1999;889:38-39.
6. US Code of Federal Regulations, Title 21, Vol. 7, Part 600.3 (General Provisions, Definitions), Revised as of April 1, 2004, 21 CFR 600.3.
7. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Assay method for the determination of the virus content of poliomyelitis vaccine (oral). Technical Report Series (TRS) 2002;904:71.
8. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Proposed assay method for determining the virus content of live measles vaccine. Technical Report Series (TRS) 1994;840:173-74.
9. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Proposed assay method for determining the virus content of live mumps vaccine. Technical Report Series (TRS) 1994;840:185-86.
10. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Proposed assay method for determining the virus content of live rubella vaccine. Technical Report Series (TRS) 1994;840:196.
11. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Requirements for yellow fever vaccine. Technical Report Series (TRS) 1998;847:43-44.
12. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Requirements for Dried BCG Vaccine. Technical Report Series (TRS) 1987;745:76.
13. Ivanoff B., Levine M.M., and Lambert P.H. WHO Global Programme for Vaccines and Immunization. Vaccination against typhoid fever: present status. Bull WHO 72 6 (1994) 957-971
14. FDA Summary of basis for approval, Carticel, Genzyme Tissue Repair (1997). http://www.fda.gov/cber/sba/autogen082297-sba.pdf
15. Development of therapeutic cancer vaccines. In: Brown F., and Petricciani J. (Eds). Developmental Biology vol. 116 (2004), Karger, Basel 69-76
16. Rosenberg S.A. Progress in human tumor immunology and immunotherapy. Nature 411 (2001) 380
17. Van den Ende B.J., and van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 9 (1997) 684
18. Irie R.F., and Morton D.L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83 (1986) 8694-8698
19. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 5594 (2002 Oct 25) 850-854
20. Rosenberg S.A., Zhai Y., Yang J.C., Schwartzentruder D.J., Hwu P., Marincola F.M., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90 24 (1998 Dec 16) 1894-1900
21. Jager E., Ringhoffer M., Dienes H.P., Arand M., Karbach J., Jager D., et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67 1 (1996 Jul 3) 54-62
22. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Assay method for the determination of the virus content of poliomyelitis vaccine (oral). Technical Report Series (TRS) 2002;904:56.
23. WHO Expert Committee on Biological Standardization. WHO Technical Report Series: Requirements for live measles vaccine. Technical Report Series (TRS) 1994;840:117-18.